RVL update on business review

  UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity --

-- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as part of our ongoing strategy to invest in UPNEEQ and drive growth --

-- The Company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden the Company’s portfolio and leverage the field force investment --

-- Second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period, highlighting lower baseline of operating expense --

-- The Company streamlined operating expense in order to extend runway, optimize marketing mix, and support strategic business development --

-- Initiated creative development for our 1st Branded Direct-to-Consumer (“DTC”) campaign --

-- E-Commerce platform, Elevate, rollout on track –

https://finance.yahoo.com/news/rvl-pharmaceuticals-plc-reports-second-105000007.html